Proposed and Completed Offers, Acquisitions, Stock Updates, and Financial Results - Analyst Notes on HCA, Tenet, UHS, Chemed, and EVHC

NEW YORK, March 17, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding HCA Holdings Inc. (NYSE:HCA), Tenet Healthcare Corp (NYSE:THC), Universal Health Services, Inc. (NYSE:UHS), Chemed Corporation (NYSE:CHE), and Envision Healthcare Holdings Inc. (NYSE:EVHC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

HCA  Holdings  Inc.  Analyst  Notes

On March 3, 2014, HCA Holdings Inc. (HCA) announced that its wholly owned subsidiary, HCA Inc., proposes to offer $3 billion aggregate principal amount of senior secured notes, subject to market and other considerations. HCA informed that the actual terms of the notes will depend on the market conditions at the time of pricing. The Company stated that net proceeds from this offering will be used by its subsidiary to redeem and repurchase the entire $1.5 billion aggregate principal amount outstanding of 8½% senior secured notes due 2019, and all of the $1.25 billion aggregate principal amount outstanding of 7⅞% senior secured notes due 2020, apart from paying related fees and general corporate purposes. The full analyst notes on HCA Holdings Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03132014/HCA/report.pdf

Tenet  Healthcare  Corp  Analyst  Notes

On March 10, 2014, Tenet Healthcare Corp (Tenet) announced that it has successfully completed the previously announced private offering of $600 million aggregate principal amount of 5.00% senior notes due 2019. Tenet stated thatproceeds from the offering will be used for general corporate expenses,which includesrepayment of indebtedness and drawings under the Company's senior secured revolving credit facility, as well as related transaction fees and expenses. The full analyst notes on Tenet Healthcare Corp are available to download free of charge at:

http://www.AnalystsReview.com/03132014/THC/report.pdf

Universal  Health  Services,  Inc.  Analyst  Notes

On March 3, 2014, Universal Health Services, Inc. (UHS) announced the completion of the acquisition of Palo Verde Behavioral Health (Palo Verde) from Tucson Medical Center. UHS stated that the acquisition establishes its presence in the Tucson market and expands its behavioral health presence in Arizona which includes Valley Hospital, an acute inpatient psychiatric hospital and Calvary Addiction Recovery Center, both located in Phoenix. The Company stated that it has also acquired a 67,324 square foot medical building in Phoenix which will beconverted into a psychiatric hospital. UHS added that Quail Run Behavioral Health in north Phoenixwill operate 100 inpatient psychiatric beds and is expected to open in the fall of 2014. The full analyst notes on Universal Health Services, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03132014/UHS/report.pdf

Chemed  Corporation  Analyst  Notes

On March 10, 2014, shares of Chemed Corporation's (Chemed) stock rose 0.51% to close at $86.44. Over the previous three-day trading session, Chemed's stock went up by2.09% while the Dow Jones Industrial Average gained 0.36% over that same period. The full analyst notes on Chemed Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03132014/CHE/report.pdf

Envision  Healthcare  Holdings  Inc  Analyst  Notes

On March 5, 2014, Envision Healthcare Holdings Inc (EVHC) released its Q4 2013 and full-year 2013 financial results. Net revenues for Q4 2013 grew 13.0% YoY to $984.8 million; full-year 2013 revenues also grew 13.0% YoY to $3.7 billion. EVHC generated net income attributable to the Company of $7.9 million in Q4 2013 compared to $12.3 million Q4 2012. The Company stated that the decrease in net income  was mainly due to the tax-effected impact of $38.7 million in costs related to the partial redemption of the 8.125% Senior Notes due 2019 (2019 Notes) on December 30, 2013, partially offset by lower interest expense due to debt reduction from IPO proceeds in August 2013. EVCH's full-year 2013 net income attributable to the Companywasc.$6 million, compared to $41.2 million in full-year 2012. According to the Company, net income for full year 2013 was affected by $88.4 million from the IPO-Related Costs in Q3 2013, along with the early redemption costs for the PIK Notes and 2019 Notes. Further, EVCH stated thatit is reaffirming its previously announced full-year 2014 guidance with Adjusted EPS of $1.10 to $1.15 and Adjusted EBITDA of $538 million to $545 million. The full analyst notes on Envision Healthcare Holdings Inc are available to download free of charge at:

http://www.AnalystsReview.com/03132014/EVHC/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR  NOTES:

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For  any  urgent  concerns  or  inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE  PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT  FINANCIAL  ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO  WARRANTY  OR  LIABILITY  ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review